Anaveon To Take A Different Clinical Path With Novel IL-2 Therapy

Interleukin-2 Agonist Being Assessed In Solid tumors

 
• By Sten Stovall
  
Cancer cells on scientific background.3d illustration
Anaveon CEO Tells Scrip Compound Can Improve On Limitations Posed By Interleukin-2 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D